Can you patent a gene? Not a gene as it exists in nature. Since the Supreme Court’s June 13, 2013 decision in Association for Molecular Pathology v. Myriad Genetics, a stretch of DNA that sits in your genome is a product of nature in US law, and cutting it out of the chromosome does not change that. What you can still patent is something people made: synthetic cDNA, sequences altered from nature, and the tests, methods and drugs built around a gene. Checked against US federal law as of October 10, 2026.
The rule sounds simple, and the practical edges are not. Here is where the line sits, why it sits there, and what Congress is arguing about right now.
The short answer, as a table
| Claimed subject matter | Patent eligible in the US? | Why |
|---|---|---|
| A naturally occurring gene, isolated from the body | No | Product of nature; isolation alone adds nothing |
| cDNA made in a lab from messenger RNA | Generally yes | Not naturally occurring as a molecule |
| A gene sequence you altered on purpose | Yes, if the change is real and claimed | Nature did not produce that order of nucleotides |
| A diagnostic or treatment method using a gene | Depends | Other doctrines apply, including the Mayo line of cases |
| A cloned animal that is an exact genetic copy | No | Not markedly different from the original |

What Myriad actually decided
Myriad Genetics had patents covering isolated DNA for the BRCA1 and BRCA2 genes, whose variants are linked to inherited breast and ovarian cancer risk. The case before the Supreme Court concerned nine composition claims drawn from three of those patents. Justice Thomas wrote the Court’s opinion (Justia, 569 U.S. 576).
The Court split the claims in two. Isolated natural DNA fell on the unpatentable side: Myriad had found something valuable, but finding it is not inventing it. Cutting the gene out of the chromosome broke chemical bonds, yet the information in the sequence stayed exactly what nature wrote. Complementary DNA, or cDNA, went the other way. A cDNA molecule is built in the lab from the coding portions of a gene and is not found in that form in nature, so it can qualify.
Two things the Court did not decide are easy to miss. No method claims were before it. And it left open DNA whose natural order of nucleotides has been changed. Both gaps matter in practice.
How the Patent Office applied it
The USPTO did not wait. On the day of the decision, June 13, 2013, it sent examiners a memo telling them to reject product claims aimed solely at naturally occurring nucleic acids or fragments, isolated or not (USPTO memo). The same memo said claims limited to non-naturally-occurring nucleic acids, cDNA for example, remain eligible, as do sequences whose natural order has been altered. Method claims involving natural nucleic acids were to be checked under the existing eligibility guidance, with fuller instructions promised later.
So the examiner’s question became practical: is the claimed thing different from what nature produces, or is it nature with a label on it?
What is still patentable
- cDNA. Lab-made, coding-only copies of genes remain claimable, which is why cDNA constructs show up in expression systems and vaccines.
- Engineered sequences. A variant you designed, with a different order of building blocks, falls outside the natural-product bar so long as the claim captures the change.
- New uses and methods. A way of treating a disease, editing a cell or manufacturing a protein is a process, not a product of nature. These claims face their own tests, covered below.
- Vectors, cell lines and organisms you modified. The question is whether the claimed thing has markedly different characteristics from anything natural.
The cloned-animal footnote: Roslin
The same logic reached beyond DNA. In In re Roslin Institute (Edinburgh), decided May 8, 2014, the Federal Circuit held that claims to live-born clones of existing farm mammals were not eligible (opinion). The clones were exact genetic copies of their donors, and the court found no markedly different characteristics from what nature already produces. This was the Dolly the sheep line of claims. The process of cloning was never the problem; the animal itself was.
Methods and diagnostics: the harder half
If gene products are settled, gene-related methods are not. A diagnostic that reads a natural correlation between a gene variant and a disease risks being treated as a law of nature, and the Court’s earlier Mayo v. Prometheus decision is the reason diagnostics companies complain that their inventions are hard to protect. Myriad did not address that.
The tension is that one side of this debate worries about too little patent protection and the other about too much. Patent holders in diagnostics say uncertainty discourages investment. Clinical laboratories say that broad gene-related patents can stop them from offering tests at all.

How a claim gets sorted: three quick examples
Abstract rules are easier to hold onto with cases in hand. These are illustrations of the reasoning, not real patents.
- Claim: “An isolated DNA molecule having the sequence of a human tumor-suppressor gene.” This is the Myriad claim in miniature. The molecule is the same one nature makes, so it fails.
- Claim: “A cDNA molecule encoding that protein, lacking the non-coding segments.” The molecule was built in a lab and does not exist in the cell in that form. This one has a path to eligibility, though it still has to be new and non-obvious like any invention.
- Claim: “A vector carrying a gene with a specific substitution that makes the protein more stable.” The altered order of nucleotides is the point of the claim. If the change is written into the claim, the natural-product objection falls away.
Eligibility is only the first gate. A cDNA claim that clears it must still be novel, non-obvious, and described well enough that a skilled person could make it. Many gene-related applications fail later, on those other grounds.
What changed for patients and labs
The practical effect of Myriad is easiest to see on the testing side. Before 2013, a company holding claims on a natural gene could, in principle, assert them against anyone who sequenced it. Once the natural sequence itself was off the table, the barrier to offering a test that reads that sequence dropped.
That is why the 2026 hearing mattered to laboratory directors. One witness described having to stop a clinical genetic-testing service because of gene-patent enforcement, according to the hearing summary cited below.
Companies that invest in sequencing, interpreting variants and building curated databases argue the reverse: without strong protection, the incentive to do that work weakens. Many protect those assets through trade secrets and contracts instead of patents, a choice with its own trade-offs.
Why drafting matters more than the label
Patent attorneys now spend real effort on how a gene-related claim is worded. A claim that recites only the natural sequence is dead on arrival. A claim that recites a lab-made molecule, a specific alteration, a new use or a manufacturing step stands a better chance, provided the written description backs it up. The lesson from Myriad is less that gene inventions are barred than that the inventive step has to be something a person did, not something a cell was already doing.

Where Congress stands in October 2026
The Patent Eligibility Restoration Act, S. 1546, would replace the court-made exceptions with statutory exclusions. Senators Tillis and Coons announced new bipartisan support for it on June 17, 2025. On July 14, 2026 the Senate Judiciary Committee held a full-committee hearing titled “From Genes to Machines: The Patent Eligibility Debate.”
According to a Holland & Knight summary, the bill’s text treats unmodified genes as ineligible, whether in the body or isolated from it, but says a gene is not “unmodified” if it has been purified, enriched or otherwise altered by human activity, or if it is used in a useful invention (Holland & Knight). Witnesses were split. Former USPTO Director Andrei Iancu and Sue Peschin backed the bill as a fix for diagnostics; two others opposed it as drafted. Dr. Debra Leonard warned that the “isolated” versus “purified” wording could bring back pre-Myriad exposure for clinical labs, according to a summary of the hearing. Senator Tillis said he was open to rewording so Myriad’s holding on unmodified natural sequences is preserved.
No markup or floor vote had been scheduled as of the hearing, and the Holland & Knight piece says few legislative days remain, so passage this Congress looks unlikely. Until something changes, Myriad is still the rule.
Common questions
Does this mean nobody owns a gene?
Nobody holds a patent on the natural sequence as such. People and companies still own patents on engineered versions, on cDNA constructs, and on specific uses, and may hold trade secrets or contract rights around related data.
Were old gene patents wiped out?
Myriad addressed the claims before it, and the USPTO told examiners to reject natural-sequence product claims afterward. Older patents were handled case by case, so check any specific patent directly.
Is editing a gene with CRISPR patentable?
The editing tools and methods can be, and the ownership fight over the core technology is a separate story.
Is isolating a new gene from a rare plant different?
Not under the Myriad reasoning. If the claim covers the natural sequence, the discovery does not make it an invention, however much effort went into finding it.
This is general information about US law, not legal advice.
Sources
- Justia, Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)
- USPTO, guidance memo following Myriad (June 13, 2013)
- Federal Circuit, In re Roslin Institute (Edinburgh), No. 2013-1407
- Holland & Knight, Is the 4th Time a Charm? Congress Revisits Patent Eligibility Reform
- CASRAI, Senate Judiciary PERA hearing 2026
- Senator Tillis, PERA announcement (June 17, 2025)
